For retail sale medicaments with insulin or hormones or antibiotics market in Portugal

Earlier Report Observations

Between 2018 and 2020, the market for retail-packed medicaments containing insulin, hormones, or antibiotics in Portugal expanded from 143.9 million USD to 183.8 million USD. This growth aligned with rising demand for obesity medications, whose sales began a gradual increase from 2019, while ongoing regulatory rules requiring sale by qualified pharmacists under Decree-Law 134/2005 provided a stable market framework.

Market size dipped to 171.6 million USD in 2021 despite an 18.7% rise in obesity drug sales that year. Recovery to 175.7 million USD by 2022 was supported by the introduction of EU Regulation 2022/123, which strengthened the European Medicines Agency's role in managing medicine availability and created task forces to address shortages, ensuring smoother market operations.

Subsequent years saw import values surge to 526.0 million USD in 2025 and exports more than double by 2023, driven by sharply rising obesity drug sales that grew 44.9% in 2024 and then nearly quintupled in 2025. Reinforced European rules on medicine availability and enhanced cooperation among member states further facilitated market integration and growth.

Production for retail sale medicaments with insulin or hormones or antibiotics in Portugal

In value, 2018-2021, K $ US

In Portugal, production of retail sale medicaments containing insulin, hormones, or antibiotics declined for the second consecutive year. In 2021, output was valued at 9 930 thousand US dollars, marking a 33.9% decrease compared to 2020. Over the period from 2018 to 2021, production fell by 21.1%, with a compound annual growth rate (CAGR) of -7.6%. The peak value was recorded in 2019 at 18 522 thousand US dollars, which also saw the largest annual increase of 47.1%.

Annual dynamics of production in Portugal in value, 2018-2021, K $ US

Exports for retail sale medicaments with insulin or hormones or antibiotics from Portugal

Exports in kind, t

Following two years of decline, exports of retail sale medicaments containing insulin, hormones, or antibiotics from Portugal increased in 2021. Portugal exported 621.7 tonnes of these products, up 13.1% year-on-year. From 2018 to 2021, exports grew by 8.9%, with a CAGR of 2.9%. The lowest volume was recorded in 2020 at 549.7 tonnes, which also experienced the largest annual decline of 3.4%.

Annual dynamics of product's exports from Portugal in kind, 2018-2021, t

Between 2018 and 2021, France, Switzerland, and the United States were the principal destinations for Portugal's exports of these medicaments in kind. France accounted for 33.9% of exports, Switzerland for 18.1%, and the United States for 11.9%, together representing 64.0% of total export flows.

Structure of product's exports in kind by countries, 2018-2021

World map of product's exports from Portugal in kind, 2018-2021

Exports in value, M $ US

Portugal's exports of retail sale medicaments containing insulin, hormones, or antibiotics increased for the second consecutive year in 2021, totalling 52.6 million US dollars, a 7.1% rise from the previous year. From 2018 to 2021, exports grew by 32.3%, equating to a CAGR of 9.8%. The lowest value was recorded in 2019 at 35.6 million US dollars, which saw the largest annual decline of 10.5%. In contrast, the largest increase occurred in 2020, with a 38.0% rise.

Annual dynamics of product's exports from Portugal in value, 2018-2021, M $ US

Over the period 2018–2021, no single market dominated Portugal's exports of these medicaments in value terms. The United States accounted for 29.9% of exports, France for 11.1%, and Mexico for 8.0%, together representing 49.0% of total export value. The remaining 51.0% was distributed among numerous smaller partners, each with modest individual shares.

Structure of product's exports in value by countries, 2018-2021

World map of product's exports from Portugal in value, 2018-2021

Imports for retail sale medicaments with insulin or hormones or antibiotics to Portugal

Imports in kind, t

After two years of growth, imports of retail sale medicaments containing insulin, hormones, or antibiotics into Portugal declined in 2021. Portugal imported 794.0 tonnes, reflecting an 11.2% decrease compared to 2020. From 2018 to 2021, imports fell by 10.4%, with a CAGR of -3.6%. The highest volume was recorded in 2020 at 894.6 tonnes, while the largest annual increase occurred in 2019 at 0.8%.

Annual dynamics of product's imports to Portugal in kind, 2018-2021, t

Between 2018 and 2021, Germany, France, and Spain were the main sources for Portugal's imports of these medicaments in kind. Germany accounted for 26.2% of imports, France for 16.3%, and Spain for 14.5%, together making up 57.0% of total import flows.

Structure of product's imports in kind by countries, 2018-2021

World map of product's imports to Portugal in kind, 2018-2021

Imports in value, M $ US

Following two years of growth, imports of retail sale medicaments containing insulin, hormones, or antibiotics into Portugal declined in 2021, totalling 217.8 million US dollars, down 1.6% from 2020. Over the period 2018–2021, imports increased by 25.3%, with a CAGR of 7.8%. The peak value was recorded in 2020 at 217.8 million US dollars, while the largest annual increase occurred in 2019 at 14.7%.

Annual dynamics of product's imports to Portugal in value, 2018-2021, M $ US

The market base for Portugal's imports of these medicaments in value terms was broad from 2018 to 2021. Denmark accounted for 17.4% of imports, Spain for 15.6%, and Belgium for 14.9%, together representing 47.9% of total import flows. The remaining 52.1% was shared among many other countries.

Structure of product's imports in value by countries, 2018-2021

World map of product's imports to Portugal in value, 2018-2021